|
| 标准 |
总人口
|
良好结果
|
坏结果
|
|
|
| 性爱 |
|
|
|
|
| 雌性
(%) |
73/79(92.4) |
33/36(91.7) |
28/31(90.3) |
|
| 雄性
(%) |
6/79(7.6) |
3/36(8.3) |
3/31(9.7) |
|
|
| 岁数年份平均++SD |
33+12 |
31.5+12.7 |
++11.4 |
|
|
| 时间诊断数月中位数 |
2(1-48) |
4.7(1至48) |
2.8(1-8) |
|
|
| BMI诊断sq+m2级表示++SD |
++9.7 |
34.6++9.4 |
32.9++ 7.7 |
|
| BMI < 30
(%) |
21/68(30.9) |
11/32(34.4) |
9/28(32.1) |
|
| BMI30-35
(%) |
13/68(19.1) |
5/32(15.6) |
8/28(28.6) |
| BMI35-40
(%) |
11/68(16.2) |
5/32(15.6) |
4/2814.3 |
| BMI > 40
(%) |
23/68 |
11/32(34.4) |
7/28(25) |
|
| CSF开关压力mmCSF中位数 |
285(150-540) |
260(170-420) |
305(150-540) |
|
|
| 诊断信号 |
|
|
|
|
| 头痛
(%) |
65/79(82.3) |
27/36(75) |
27/31(87) |
|
| Papilledema
(%) |
75/78(96) |
35/36(97) |
31/31(100) |
|
| 可视性中位数 / |
8.25 |
8.5 |
8.3 |
|
| 瞬态视觉蒙蔽
(%) |
14/79(17.7) |
5/36(13.8) |
5/31(16.1) |
|
| 可视场缺陷
(%) |
62/71(87.3) |
28/32(87.5) |
26/28(93) |
|
| 目视跟踪缺陷
(%) |
12/79 (15.2) |
9/36(25) |
3/31(9.7) |
|
| 提尼图斯
(%) |
10/79(12.7) |
4/36(11) |
6/31(19.3) |
|
| 头晕
(%) |
9/79(11.4) |
3/36(8.3) |
6/31(19.3) |
|
|
| 辐射标志 |
|
|
|
|
| 空sella
(%) |
45/79(57) |
22/36(61) |
19/31(61.3) |
|
| 光神经层放大
(%) |
51/79(64.6) |
21/36(58.3) |
22/31(71) |
|
|
| 跨向弦 |
|
|
|
|
| 常态化
(%) |
5/58(8.6) |
3/26(11.5) |
0/28 |
|
| 希波拉西亚
(%) |
5/58(8.6) |
3/26(11.5) |
2/28(7.1) |
|
| 单体加速度
(%) |
5/58(8.6) |
4/26(15.5) |
1/28(3.6) |
|
| 双边神经质疏松
(%) |
43/58(74) |
16/26(61.5) |
25/28(89.3) |
|
|
| 处理方法 |
|
|
|
|
| ecetazolide每日剂量、mg和中值 |
623 |
640 |
651 |
|
| 权值变化 |
|
|
|
<0.00
|
| 增益 > 5%
(%) |
10/4820.8 |
0/26 |
10/22(45.5) |
|
| 损耗 > 5%
(%) |
15/48(31.2) |
11/26(42.3) |
4/22(18.2) |
|
| 无更改
(%) |
23/48 |
15/26(57.7) |
8/22(36.3) |
|
|
|
